Maa: Kanada
Kieli: englanti
Lähde: Health Canada
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
APOTEX INC
J01MA14
MOXIFLOXACIN
400MG
TABLET
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
ORAL
15G/50G
Prescription
QUINOLONES
Active ingredient group (AIG) number: 0142242001; AHFS:
APPROVED
2016-01-07
Page 1 of 66 PRODUCT MONOGRAPH PR APO-MOXIFLOXACIN Moxifloxacin Tablets 400 mg Moxifloxacin (as moxifloxacin hydrochloride) House Standard Antibacterial Agent APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 CANADA Date of Revision: August 31, 2020 SUBMISSION CONTROL NO: 240946 Page 2 of 66 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 5 WARNINGS AND PRECAUTIONS ......................................................................................... 6 ADVERSE REACTIONS ......................................................................................................... 14 DRUG INTERACTIONS ......................................................................................................... 18 DOSAGE AND ADMINISTRATION ..................................................................................... 20 OVERDOSAGE ........................................................................................................................ 21 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 22 STORAGE AND STABILITY ................................................................................................. 29 SPECIAL HANDLING INSTRUCTIONS ............................................................................... 29 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 29 PART II: SCIENTIFIC INFORMATION ....................................................................................... 31 PHARMACEUTICAL INFORMATION ................................................................. Lue koko asiakirja